More MS news articles for March 2001

Viragen Commences Legal Action Citing Illegal Use Of Internet Message Boards
 
http://finance.individual.com/display_news.asp?doc_id=PR20010305FLM006&page=news

Monday March 5  9:44am
Source: PR Newswire

PLANTATION, Fla., March 5 /PRNewswire/ -- Viragen, Inc. (Amex: VRA) today announced the filing of a defamation, slander and libel lawsuit in the Circuit Court of the 17th Judicial Circuit In and For Broward County, Florida. A Company spokesperson stated that this is the first in a series of vigorous legal actions against named Internet users. The lawsuit alleges that false, misleading, malicious and untrue statements were intentionally made by the defendants. Viragen is seeking damages and has reserved its right to amend the Complaint to seek punitive damages in excess of $1,000,000.

Mr. Carl Singer, Viragen's Chairman Emeritus, stated, "Viragen will not tolerate any illegal attempts to spread libelous or defamatory information."

In this case it is alleged that the defendants systematically drafted, communicated, published and disseminated under one or more aliases a series of maliciously false and defamatory publications over the World Wide Web via the Raging Bull(TM) Message Board.

Viragen, Inc. is engaged in the research, development and manufacture of immunomodulatory therapeutic products including natural human interferon and human monoclonal antibodies for the treatment of various life-threatening and debilitating diseases such as hepatitis B & C, multiple sclerosis and cancer.

In addition to developing a portfolio of proprietary cancer-fighting drugs, Viragen is engaged in a project designed to deliver efficient, cost- effective alternatives to the biopharmaceutical industry for the large-scale production of protein-based drugs. Viragen holds the worldwide exclusive license to commercialize "Avian (bird) Transgenic Technology" which promises a much faster, cost-effective and virtually unlimited production process.

Please contact them for your free copy of Viragen's latest VHS video, "The Avian Project."

    Corporate Contacts:
    Mel Rothberg, Executive Vice President
    Phone: (954) 233-8746; Fax: (954) 233-8743
    E-mail: mrothberg@viragen.com

    Douglas Calder, Director of Communications
    Phone: (954) 233-8746; Fax: (954) 233-1414
    E-mail: dcalder@viragen.com

For more information please visit our Web site at www.viragen.com or contact "Company News On Call" at (800) 758-5804, followed by extension 116574.

The foregoing press release contains forward-looking statements that can be identified by such terminology such as "expects," "potential," "suggests," "may," "will," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research development results could be affected by, among other things, uncertainties relating to clinical trials and product development; unexpected regulatory delays or government regulation generally; the Company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general.

Source: Viragen, Inc.
Contact: Mel Rothberg, Executive Vice President, 954-233-8746, or fax, 954-233-8743, or e-mail, mrothberg@viragen.com, or Douglas Calder, Director of Communications, 954-233-8746, fax, 954-233-1414, or e-mail, dcalder@viragen.com